Please login to the form below

Not currently logged in
Email:
Password:

GSK to donate 50m H1N1 vaccines

GlaxoSmithKline (GSK) has signed an agreement with the World Health Organisation (WHO) to donate 50 million doses of its adjuvanted H1N1 influenza vaccine to WHO for distribution to developing countries most in need
GlaxoSmithKline (GSK) has signed an agreement with the World Health Organisation (WHO) to donate 50 million doses of its adjuvanted H1N1 influenza vaccine to WHO for distribution to developing countries most in need.

Andrew Witty, CEO, GlaxoSmithKline said: “GSK is committed to supporting governments and health authorities around the world in their efforts to protect their populations against this pandemic. Our commitment recognises the needs of developing countries and this donation of 50 million doses will enable vaccination to begin soon in the some of the world's poorest countries.”

In addition to the donation, GSK is also supplying its vaccine to developing countries under a tiered-pricing policy based on World Bank classification and GAVI eligibility. GAVI-eligible countries, which include the world's poorest, would receive highly preferential prices based on volume orders.

Dr Margaret Chan, director-general, WHO said: “We welcome this very generous donation by GSK, which will go to protect the health of the world's poorest people. This is a real gesture of global solidarity towards those who would not otherwise be able to have access to this vaccine. WHO will now work to see that these vaccines are distributed to those who need them.”

GSK has allocated 20 per cent of overall production of its Canadian manufacturing site to developing countries. The donation to WHO is part of this allocation.

10th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics